Perlman S E, Rudy S J, Pinto C, Townsend-Akpan C
Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Louisville, Kentucky, USA.
J Reprod Med. 2001 Feb;46(2 Suppl):153-61.
Upon completion of this article, the reader should be able to: 1. Identify the dermatologic drugs with the highest risk of teratogenicity. 2. List the essential information to be obtained from a woman with childbearing potential being considered for treatment with a teratogenic dermatologic agent. 3. Discuss management principles for administration of teratogenic agents to women with childbearing potential. Dermatologic agents can be highly teratogenic, and the gynecologist must be aware of the issues involved in prescribing them. Prescribers should be aware of the risks and ensure that patients taking teratogens do not become pregnant during the course of therapy (or until the drug has been cleared from the body). This can involve taking menstrual and sexual histories and counseling the patient about sexual behavior and contraception.
读完本文后，读者应能够：1. 识别致畸性风险最高的皮肤科药物。2. 列出从有生育潜力且考虑用致畸性皮肤科药物治疗的女性那里应获取的基本信息。3. 讨论对有生育潜力的女性使用致畸性药物的管理原则。皮肤科药物可能具有高度致畸性，妇科医生必须了解开具此类药物所涉及的问题。开处方者应知晓风险，并确保服用致畸药物的患者在治疗期间（或直到药物从体内清除）不会怀孕。这可能涉及询问月经史和性史，并就性行为和避孕问题向患者提供咨询。
